514 related articles for article (PubMed ID: 18266660)
1. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
Lip GY; Frison L; Grind M;
J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypertension on anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M;
Eur Heart J; 2007 Mar; 28(6):752-9. PubMed ID: 17289744
[TBL] [Abstract][Full Text] [Related]
3. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
4. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
[TBL] [Abstract][Full Text] [Related]
5. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
7. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M
J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
[TBL] [Abstract][Full Text] [Related]
9. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
11. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
13. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Agarwal S; Hachamovitch R; Menon V
Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
[TBL] [Abstract][Full Text] [Related]
14. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Nieuwlaat R; Dinh T; Olsson SB; Camm AJ; Capucci A; Tieleman RG; Lip GY; Crijns HJ;
Eur Heart J; 2008 Apr; 29(7):915-22. PubMed ID: 18334476
[TBL] [Abstract][Full Text] [Related]
15. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
16. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Gjesdal K; Feyzi J; Olsson SB
Heart; 2008 Feb; 94(2):191-6. PubMed ID: 17483128
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation in atrial fibrillation.
Anderson M; Kirk M
Med Health R I; 2004 Apr; 87(4):98-100. PubMed ID: 15168633
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
19. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
Waldo AL; Becker RC; Tapson VF; Colgan KJ;
J Am Coll Cardiol; 2005 Nov; 46(9):1729-36. PubMed ID: 16256877
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
Thromb Haemost; 2009 May; 101(5):938-42. PubMed ID: 19404548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
